The review of new data on the study of bifidobacterial factors of different origin and the probable mechanisms of their favorable action on the microflora of the intestinal tract if presented. The main emphasis is made on the analysis of data on the use of oligosaccharides, including fructo-oligosaccharides, as compounds stimulating the growth and development of bifidobacteria both in pure cultures and in intestinal microflora. Methods for the treatment of natural compounds with a view to enhancing their bifidogenic effect are presented. The possibilities and/or advantages of using bifidogenic factors in vivo and in vitro as medicinal preparations either alone or incorporated in probiotic compositions are evaluated. Suggestion has been made that the choice of the method for using bifidogenic factors may depend on the kind and severity of disturbances in indigenous microflora.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bifidogenic Effect of Human Milk Oligosaccharides on Pediatric IBD Fecal Microbiota.
Microorganisms
September 2024
Health, Nutrition & Care (HNC), DSM-Firmenich, 4303 Kaiseraugst, Switzerland.
The prevalence of pediatric inflammatory bowel disease (pIBD) has been increasing over the last two decades. Yet, treatment strategies are still limited, in part due to the multifactorial nature of the disease and the complex interplay between genetic, environmental, dietary, immune, and gut microbial factors in its etiology. With their direct and indirect anti-inflammatory properties, human milk oligosaccharides (HMOs) are a promising treatment and management strategy for IBD.
View Article and Find Full Text PDFLactobacilli and Bifidobacteria: A Parapostbiotic Approach to Study and Explain Their Mutual Bioactive Influence.
Foods
September 2024
Department of Agriculture, Food, Natural Resources and Engineering, University of Foggia, 71122 Foggia, Italy.
Three strains of and three bifidobacteria ( subsp. , , and ) were used as target strains; in addition, for each microorganism, the cell-free supernatant (CFS) was produced and used as an ingredient of the growth medium. Namely CFSs from lactobacilli were used on bifidobacteria and CFSs from bifidobacteria were used on lactobacilli.
View Article and Find Full Text PDFCabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Nat Med
September 2024
Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect on those receiving tyrosine kinase inhibitor-based combinations is unknown. In this open-label, randomized, investigator-initiated, phase 1 study, 30 participants with locally advanced or mRCC with histological confirmation of clear cell, papillary or sarcomatoid component were randomized in a 2:1 fashion to receive cabozantinib (an inhibitor of vascular endothelial growth factor receptor, MET and AXL) and nivolumab (anti-programmed cell death protein 1) with or without CBM588 as first-line treatment.
View Article and Find Full Text PDFIdentification of carbohydrate gene clusters obtained from in vitro fermentations as predictive biomarkers of prebiotic responses.
BMC Microbiol
May 2024
Nebraska Food for Health Center, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA.
Background: Prebiotic fibers are non-digestible substrates that modulate the gut microbiome by promoting expansion of microbes having the genetic and physiological potential to utilize those molecules. Although several prebiotic substrates have been consistently shown to provide health benefits in human clinical trials, responder and non-responder phenotypes are often reported. These observations had led to interest in identifying, a priori, prebiotic responders and non-responders as a basis for personalized nutrition.
View Article and Find Full Text PDFBenefits and Challenges of Encapsulating Bifidobacterium Probiotic Strains with Bifidogenic Prebiotics.
Probiotics Antimicrob Proteins
October 2024
Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Food Technology, Camino Arenero #1227, El Bajío del Arenal, 45019, Zapopan, Jalisco, A.C. (CIATEJ), Mexico.
Bifidobacteria offer remarkable health benefits when added to probiotic formulations, contributing to the burgeoning market driven by increased awareness among consumers and healthcare providers. However, several pivotal challenges must be crossed: strain selection, encapsulation wall materials, compatible food matrices, and the intricate interplay among these factors. An approach to address these challenges involves exploring bifidogenic substrates as potential encapsulation materials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!